癌症研究
免疫疗法
T细胞
细胞毒性
细胞
细胞毒性T细胞
CD5型
白细胞介素15
嵌合抗原受体
白细胞介素12
自然杀伤细胞
抗原
化学
白细胞介素21
耐火材料(行星科学)
受体
白细胞介素2
生物
免疫学
医学
T细胞受体
癌症免疫疗法
效力
淋巴因子激活杀伤细胞
细胞培养
分子生物学
NK-92
免疫系统
毒性
抗原提呈细胞
作者
Yang Chen,Ping Wang,Mingjun Yang,Huaqing Lu,Qizhong Lu,Zongliang Zhang,Zeng Wang,Zhixiong Zhu,Hexian Li,Wanqin Zeng,Zhengyu Yu,Meng Li,Liang Zhao,Bo Ling,Wei Wang,Hai Yi,Yi Xiong,Ting Niu,Aiping Tong
标识
DOI:10.1016/j.xcrm.2025.102409
摘要
The poor prognosis of patients with recurrent or refractory T cell malignancies emphasizes the need for improved immunotherapies. CD5 is a characteristic marker of malignant T cells and is expressed on almost all normal T cells. Therefore, for treating T cell malignancies, focusing on natural killer (NK) cells lacking CD5 expression may elicit a better safety profile than that by T cell-based therapies. We generate a CD5-targeted NK cell engager (NKCE) through the specific binding of CD16a nanobody and a high-affinity anti-CD5 antibody. Its antitumor potency is demonstrated in vitro. After incorporating interleukin (IL)-15Rα/IL-15, the modified tri-NKCE exhibits stronger antitumor efficacy against CD5+ malignant tumor cells, with the production of more cytokines and chemokines. In vivo, tri-NKCE exhibits stronger cytotoxicity by enhancing NK cell proliferation. Compared with chimeric antigen receptor (CAR)-T cells, this tri-NKCE exhibits no toxicity to normal T cells. In conclusion, tri-NKCE offers a safer and cost-effective immunotherapy against T cell malignancies.
科研通智能强力驱动
Strongly Powered by AbleSci AI